Rutie Yin
West China Second University Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Rutie Yin as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 01:59 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT06333821 · A Study of Nimotuzumab Plus Concurrent Chemoradiotherapy Sequential Maintenance Treatment for Cervical CarcinomaBiotech Pharmaceutical Co., Ltd. · not yet recruiting · Cervical Cancer · study chair
- Ph1NCT05866354 · To Evaluate Pharmacokinetics of Tisotumab Vedotin in Chinese Subjects With Metastatic or Recurrent Solid MalignanciesZai Lab (Shanghai) Co., Ltd. · completed · Solid Malignancies · principal investigator
- Ph2NCT04392102 · A Study of Niraparib in Patients With Relapsed Ovarian CancerZai Lab (Shanghai) Co., Ltd. · completed · Ovarian Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 01:59 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 01:59 UTC. The ranking covers the 200 most relevant of 63 PubMed records, and a shared surname and initials can bring in a namesake. All 63 on PubMed
- 228 citationsRCR 11.8
- EZH2-mediated epigenetic suppression of long noncoding RNA SPRY4-IT1 promotes NSCLC cell proliferation and metastasis by affecting the epithelial-mesenchymal transition.Cell Death Dis · 2014217 citationsRCR 6.5
- 174 citationsRCR 8.3
- Treatment With Niraparib Maintenance Therapy in Patients With Newly Diagnosed Advanced Ovarian Cancer: A Phase 3 Randomized Clinical Trial.JAMA Oncol · 2023155 citationsRCR 13.3
- 73 citationsRCR 3.9
- 67 citationsRCR 4.6
- Genomic signatures define three subtypes of EGFR-mutant stage II-III non-small-cell lung cancer with distinct adjuvant therapy outcomes.Nat Commun · 202163 citationsRCR 2.8
- Low-dose topical 5-aminolevulinic acid photodynamic therapy in the treatment of different severity of acne vulgaris.Photodiagnosis Photodyn Ther · 201358 citationsRCR 3.2
- An Open-label, Multicenter, Single-arm, Phase II Study of Fluzoparib in Patients with Germline BRCA1/2 Mutation and Platinum-sensitive Recurrent Ovarian Cancer.Clin Cancer Res · 202149 citationsRCR 2.2
- 46 citationsRCR 7.3